PL444722A1 - Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym - Google Patents

Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym

Info

Publication number
PL444722A1
PL444722A1 PL444722A PL44472223A PL444722A1 PL 444722 A1 PL444722 A1 PL 444722A1 PL 444722 A PL444722 A PL 444722A PL 44472223 A PL44472223 A PL 44472223A PL 444722 A1 PL444722 A1 PL 444722A1
Authority
PL
Poland
Prior art keywords
liposome
cancer activity
drug delivery
drugs
weight
Prior art date
Application number
PL444722A
Other languages
English (en)
Other versions
PL249575B1 (pl
Inventor
Olga Święch
Agata KRZAK
Joanna PIETRAS
Weronika PIOTROWSKA
Anna Boguszewska-Czubara
Mateusz Psurski
Joanna Wietrzyk
Ewa OLISZEWSKA
Joanna JAROSZ
Wojciech Smoron
Renata Bilewicz
Original Assignee
Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością filed Critical Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL444722A priority Critical patent/PL249575B1/pl
Priority to CN202480044870.0A priority patent/CN121443273A/zh
Priority to EP24740621.8A priority patent/EP4704811A1/en
Priority to PCT/PL2024/000024 priority patent/WO2024228633A1/en
Priority to IL324425A priority patent/IL324425A/en
Publication of PL444722A1 publication Critical patent/PL444722A1/pl
Publication of PL249575B1 publication Critical patent/PL249575B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia jest modyfikowany liposom do przenoszenia leków charakteryzujący się tym, że złożony jest z trzech głównych lipidów, to jest DPPC w ilości od 48,6% do 70,7% wagowych, cholesterolu w ilości od 18,3% do 18,6% wagowych, DSPE-PEG(2000)aminy w ilości od 10,6% do 10,7% wagowych oraz co najmniej jednego lipidu z grupy obejmującej DOPC i DOPG, przy czym zawartość DOPC w liposomie wynosi nie więcej niż 22,4% wagowych, a zawartość DOPG w liposomie wynosi nie więcej niż 22,6% wagowych. Kolejnymi przedmiotami zgłoszenia jest powyższy liposom do zastosowania do przenoszenia co najmniej jednego leku, zwłaszcza o działaniu antynowotworowym oraz sposób ładowania liposomu lekami zwłaszcza o działaniu antynowotworowym.
PL444722A 2023-05-03 2023-05-03 Modyfikowany liposom do przenoszenia leków, zwłaszcza o działaniu antynowotworowym PL249575B1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL444722A PL249575B1 (pl) 2023-05-03 2023-05-03 Modyfikowany liposom do przenoszenia leków, zwłaszcza o działaniu antynowotworowym
CN202480044870.0A CN121443273A (zh) 2023-05-03 2024-05-03 用于递送药物的经修饰脂质体、脂质体用于递送药物特别是具有抗癌活性的药物的用途、以及将药物特别是具有抗癌活性的药物负载到脂质体的方法
EP24740621.8A EP4704811A1 (en) 2023-05-03 2024-05-03 Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity
PCT/PL2024/000024 WO2024228633A1 (en) 2023-05-03 2024-05-03 Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity
IL324425A IL324425A (en) 2023-05-03 2024-05-03 Modified liposome for drug delivery, use of liposome for drug delivery, especially with anticancer activity, and methods of loading liposome with drugs, especially with anticancer activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444722A PL249575B1 (pl) 2023-05-03 2023-05-03 Modyfikowany liposom do przenoszenia leków, zwłaszcza o działaniu antynowotworowym

Publications (2)

Publication Number Publication Date
PL444722A1 true PL444722A1 (pl) 2024-11-04
PL249575B1 PL249575B1 (pl) 2026-05-11

Family

ID=91898578

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444722A PL249575B1 (pl) 2023-05-03 2023-05-03 Modyfikowany liposom do przenoszenia leków, zwłaszcza o działaniu antynowotworowym

Country Status (5)

Country Link
EP (1) EP4704811A1 (pl)
CN (1) CN121443273A (pl)
IL (1) IL324425A (pl)
PL (1) PL249575B1 (pl)
WO (1) WO2024228633A1 (pl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096139A1 (en) * 2015-12-03 2017-06-08 Boston Medical Center Corporation B cell-based cancer immunotherapy
EP3530266A1 (en) * 2018-02-27 2019-08-28 LipoCoat B.V. A lipid-based coating composition, and an object having a lipid-based coating
PL438742A1 (pl) * 2021-08-14 2023-02-20 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2013086526A1 (en) * 2011-12-09 2013-06-13 The Regents Of The University Of California Liposomal drug encapsulation
CN105451720A (zh) * 2013-03-13 2016-03-30 马林克罗特有限公司 用于癌症疗法的脂质体奥沙利铂组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096139A1 (en) * 2015-12-03 2017-06-08 Boston Medical Center Corporation B cell-based cancer immunotherapy
EP3530266A1 (en) * 2018-02-27 2019-08-28 LipoCoat B.V. A lipid-based coating composition, and an object having a lipid-based coating
PL438742A1 (pl) * 2021-08-14 2023-02-20 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEUNG CCL, AL-JAMAL WT: "Int J Pharm. 2019 Jul 20;566:687-696", STERICALLY STABILIZED LIPOSOMES PRODUCTION USING STAGGERED HERRINGBONE MICROMIXER: EFFECT OF LIPID COMPOSITION AND PEG-LIPID CONTENT, DOI: 10.1016/j.ijpharm.2019.06.033 *

Also Published As

Publication number Publication date
CN121443273A (zh) 2026-01-30
IL324425A (en) 2026-01-01
PL249575B1 (pl) 2026-05-11
EP4704811A1 (en) 2026-03-11
WO2024228633A1 (en) 2024-11-07

Similar Documents

Publication Publication Date Title
De Blank et al. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus
Lecube et al. Pulmonary function and sleep breathing: two new targets for type 2 diabetes care
Luks et al. COVID-19 lung injury and high-altitude pulmonary edema. A false equation with dangerous implications
Pedrazzoli et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa
Cassidy et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer
Sands Regulation of Renal Urea Transportersa
Ceresoli et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
Ferreira et al. P-glycoprotein and membrane roles in multidrug resistance
Bonomi et al. Comparison of survival and quality of life in advanced non–small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
Oudard et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer
Moudgil et al. Hypoxic pulmonary vasoconstriction
Gelmon et al. Phase I study of liposomal vincristine
Georgoulias et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial
List et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion–dependent patients with myelodysplastic syndrome
Smith et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
Rivera et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer
US9144563B2 (en) Treatment of triple receptor negative breast cancer
Rubin et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors
DeVore et al. Phase II study of irinotecan plus cisplatin in patients with advanced non–small-cell lung cancer
Pföhler et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study
Yamamoto et al. Influence of inflammation on the pharmacokinetics of perampanel
Louie et al. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis
Bolis et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial
Lee et al. Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment
Ban et al. Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer